PHASE I TRIAL OF ANTISENSE INHIBITOR OF PROTEIN KINASE C ALPHA IN CAN

$0M01FY2001RRNIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 38684815 Paper 35728925 Paper 33478957 Paper 33277303 Paper 32446491 Paper 32171899 Paper 32111975 Paper 31691959 Paper 31600550 Paper 31427096 Paper 30631138 Paper 30531941 Paper 30239722 Paper 30224653 Paper 29872859 Paper 29641994 Paper 29479291 Paper 29141982 Paper 28923095 Paper 28283553 Paper 28279433 Paper 28199816 Paper 27544837 Paper 27455401 Paper 27423510 Paper 26908487 Paper 26638192 Paper 26209223 Paper 26091977 Paper 26080344 Paper 26070913 Paper 25886831 Paper 25601310 Paper 25577655 Paper 25474559 Paper 25455511 Paper 25425651 Paper 25348129 Paper 25183760 Paper 25023551 Paper 24819305 Paper 24790261 Paper 24767622 Paper 24755714 Paper 24622517 Paper 24615880 Paper 24570214 Paper 24405552 Paper 24398043 Paper 24378638 Paper 24370654 Paper 24367114 Paper 24322171 Paper 24296717 Paper 24220913 Paper 24135709 Paper 24074694 Paper 23955431 Paper 23943230 Paper 23867958 Paper 23867957 Paper 23849514 Paper 23712984 Trial NCT01223287 Trial NCT01223261 Trial NCT01203501 Trial NCT01203488 Trial NCT01203475 Trial NCT01203449 Trial NCT01203436 Trial NCT01203423 Trial NCT01035697 Trial NCT00874367 Trial NCT00273325 Trial NCT00114543 Trial NCT00109525 Trial NCT00067613 Trial NCT00063063 Trial NCT00016523 Trial NCT00011362 Trial NCT00009646 Trial NCT00009620 Trial NCT00005777 Trial NCT00005776 Trial NCT00005775 Trial NCT00005774 Trial NCT00005773 Trial NCT00005772 Patent 8545814 Patent 7255851 Patent 7198774 Patent 6939533 Patent 6923951 Patent 6916462 Patent 6908605 Patent 6890515 Patent 6649143 Patent 6217847 Patent 6077665 Patent 5650135

Abstract

Over-expression of PKC alpha may promote the development and maintenance of tumors. We have previously reported the safety and activity of ISIS 3521 at 22 mg/kg by a 21 day continuous i.v. infusion. This study explores an alternate schedule of a 24 hour continuous infusion given weekly at 4 dose levels.

View original record on NIH RePORTER →